MN has received research grants from the Japan Agency for Medical Research and Development (AMED), the National Center for Global Health and Medicine (Japan), and Japan Ministry of Health, Labour, and Welfare for intractable adrenal diseases; has received consulting fees from Nihon Medi-Physics and honoraria for speakers' bureaus from Recordati Rare Diseases Japan, Roche Diagnostics, Teijin Home Healthcare, FUJIFILM Wako Pure Chemical, Kyowa Kirin, Sumitomo Pharma, FUJIFILM Toyama Chemical, and Daiichi Sankyo, outside the scope of this Comment; and has received honoraria for speakers' bureaus from Ono Pharmaceutical (about metyrosine) and PDRadiopharma (about radiotherapy). WFY has received consulting fees from Crinetics Pharmaceuticals for advisory board participation; and has received consulting fees from AstraZeneca Pharmaceuticals and Bayer AG for participation on a drug safety monitoring board, outside the scope of this Comment.